Clovis Oncology (NASDAQ:CLVS) Earns Hold Rating From Analysts at StockNews.com
Clovis Oncology (NASDAQ:CLVS) Earns Hold Rating From Analysts at StockNews.com
StockNews.com initiated coverage on shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) in a research note issued to investors on Tuesday. The firm issued a hold rating on the biopharmaceutical company's stock.
證券新聞網啟動對股份的覆蓋 克洛維斯腫瘤科 (NASDAQ: CLVS — 獲得評級) 在星期二發給投資者的研究報告中。該公司對該生物製藥公司的股票發出了持有評級。
Separately, JPMorgan Chase & Co. cut shares of Clovis Oncology from a neutral rating to an underweight rating in a research note on Wednesday, November 9th.
另外，摩根大通公司在 11 月 9 日（星期三）的研究報告中，將 Clovis 腫瘤學的股份從中性評級下調至體重過輕評級。
Clovis Oncology Price Performance
克洛維斯腫瘤學價格表現
The stock has a 50 day moving average of $0.52 and a 200 day moving average of $1.13. The firm has a market cap of $11.60 million, a PE ratio of -0.04 and a beta of 0.24. Clovis Oncology has a 12 month low of $0.08 and a 12 month high of $3.32.
該股票的 50 日移動平均線為 0.52 美元，200 日移動平均線為 1.13 美元。該公司的市值為 1,160 萬美元，私募股權比率為 -0.04，貝塔值為 0.24。克洛維斯腫瘤學有一個 12 個月低點 0.08 美元和 12 個月高點 3.32 美元。
Hedge Funds Weigh In On Clovis Oncology
對沖基金權衡克洛維斯腫瘤學
Institutional investors have recently bought and sold shares of the business. First Republic Investment Management Inc. purchased a new position in Clovis Oncology during the 1st quarter worth approximately $27,000. Mirabella Financial Services LLP purchased a new position in shares of Clovis Oncology during the 1st quarter valued at approximately $36,000. Sassicaia Capital Advisers LLC purchased a new position in shares of Clovis Oncology during the 1st quarter valued at approximately $40,000. Objective Capital Management LLC purchased a new position in shares of Clovis Oncology during the 2nd quarter valued at approximately $44,000. Finally, Bank of Montreal Can purchased a new position in shares of Clovis Oncology during the 1st quarter valued at approximately $48,000. 24.53% of the stock is owned by hedge funds and other institutional investors.
機構投資者最近買賣了該業務的股票。第一共和國投資管理公司在第一季度購買了克洛維斯腫瘤學的新職位，價值約為 27,000 美元。美麗貝拉金融服務有限責任公司在第一季度購買了克洛維斯腫瘤學股份的新頭寸，價值約為 36,000 美元。薩西卡亞資本顧問有限責任公司在第一季度購買了克洛維斯腫瘤學股份的新位置，價值約為 40,000 美元。客觀資本管理有限責任公司在第二季度購買了克洛維斯腫瘤學股份的新位置，價值約為 44,000 美元。最後，蒙特利爾銀行可以在第一季度購買了價值約 48,000 美元的克洛維斯腫瘤學股份的新頭寸。24.53％ 的股票由對沖基金和其他機構投資者擁有。
Clovis Oncology Company Profile
克洛維斯腫瘤公司簡介
(Get Rating)
(取得評分)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Clovis Oncology, Inc 是一家生物製藥公司，致力於在美國、歐洲和國際上收購、開發和商業化抗癌藥物。其商業產品包括 Rubraca（rucaparib）片劑，一種小分子聚 ADP-核糖聚合酶抑製劑，用於治療與晚期卵巢癌有害 BRCA 突變的患者的單一療法，並通過 FDA 批准的伴侶診斷為 Rubraca 選擇治療。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
- 3 High-Yield Dividend Stocks to Hold for the Long Haul
- Cal-Maine Posts Record Quarter, Remain CALM Income Investors
- Tesla Stock: What the Bulls and the Bears Are Getting Wrong
- 獲取有關克洛維斯腫瘤學（CLVS）的研究報告的免費副本
- 你應該熱身 Generac 股票的冬天嗎？
- 金塔拉治療學是一個隱藏的寶石嗎？
- 3 支長期持有的高收益股票
- 卡爾-緬因州發布創紀錄的季度，保持冷靜收入投資
- 特斯拉股票：公牛和熊出錯了什麼
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接收克洛維斯腫瘤日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Clovis 腫瘤學和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。